to be demonstrated. A better description of PE in a SA setting would be useful in efforts to improve patient management and subsequent patient outcomes in this setting. Therefore, the aim of this research was to improve the current understanding of PE in a SA setting. The objectives of this research were to:
INTRODUCTION

Pulmonary embolism (PE) is an important complication of deep vein thrombosis (DVT).
(1) Both PE and DVT are manifestations of venous thromboembolism (VTE). An incidence rate of nearly 1.0 case per 1 000 people has been reported for PE in North American/European settings. (2) Mortality is much higher in patients with undiagnosed, untreated PE. (3) Therefore, a better understanding of the presentation of PE is required, such that patients can be diagnosed timeously and treatment can be initiated. (4) However, the presentation of PE itself is highly variable and can pose diagnostic challenges. (2, 4, 5) While there are no specific data available for PE in a South African (SA) setting, a 2007 report found 2 566 deaths in the country could be attributed to diseases of the circulatory system -a composite measure that includes PE, stroke, and myocardial infarction. (6) Interestingly, embolic pathophysiology also appears to play some role in stroke and myocardial infarction. (7, 8) While descriptions of PE in SA settings are rare, recent evidence from a study of DVT in a SA setting suggests that there might be some setting-specific differences in the characteristics and risk factors for VTE between SA and overseas settings. (9) It is pos- 
Data collection
The medical records of all patients included in this research were reviewed, and information related to patient demographics, clinical presentation, potential risk factors, classification and treatment of PE, and inpatient mortality, was collected using a paper-based data collection tool. Massive PE was defined as PE with haemodynamic instability. Submassive PE was defined as PE with haemodynamic stability and evidence of right ventricular dysfunction (as per echocardiogram) or myocardial necrosis (elevated troponin). (10) Minor PE was defined as PE that did not satisfy the criteria for the massive or submassive categories. All data were transferred to an electronic spreadsheet in preparation for statistical analyses.
Statistical analysis
We analysed our data using descriptive statistical methods. 
Ethical approval
DISCUSSION
There are only a few published CS of VTE from SA settings. (9, 11) These CS are predominantly comprised of patients with DVT.
Our CS differs from these in that we report on a much larger CS of SA patients with PE. We identified 61 cases who were admitted for PE at our institution over a 5-year period. Our findings are in line with a previous report on the rarity of PErelated admissions at SA tertiary-level hospitals. (11) Our CS was of similar age to that reported in the SA study of Goldstein and Wu. (11) However, our CS was younger than that reported for PE in developed countries, such as the United
States. (12) The younger age of SA patients with VTE (when compared with CS in developed countries) can most likely be attributed to the high HIV prevalence in SA, and the HIVassociated coagulopathy in these younger patients. (11) Most of our CS was of black African ethnicity and female. This is in keeping with existing evidence from both SA and overseas settings suggesting a higher incidence of VTE in persons of black African ethnicity and in women. (13, 14) The basis for the higher incidence of VTE among persons of black African ethnicity appears to be genetic, (13) while the formation of larger platelet aggregates in women has been proposed as an explanation for the higher incidence of VTE in this group. (14) The SA study of Goldstein and Wu did not report on the signs and symptoms of PE. (11) The most common clinical symptoms of PE in our CS were dyspnoea and chest pain, while the most common clinical signs in our CS were tachypnea and tachycardia. Our findings for PE symptoms/signs are similar to those reported in the overseas literature, in that tachypnea and tachycardia are reported as common clinical signs of PE. (4, 15) However, the frequency of these reported symptoms/ signs appears to differ between SA and overseas settings. For instance, we report a higher frequency of dyspnoea and a lower frequency of chest pain when compared with overseas settings. (4, 15) With regard to PE signs, we report a lower frequency of tachypnea, but a higher frequency of tachycardia when compared with overseas settings. (4, 15) Some clinical symptoms/signs are included in clinical prediction rules for PE.
Therefore, it is possible that clinical prediction scores derived from studies performed in other countries may not be applicable in a SA setting. This might necessitate the development of setting-specific clinical prediction rules for PE.
The most common PE risk factors in our CS were cardiac failure and obesity. Our findings are very different from those of Goldstein and Wu, who reported HIV and tuberculosis to be the most common risk factors in SA patients with VTE. (11) It is possible that the preponderance of cases with DVT in the study of Goldstein and Wu might be an explanation for this difference in findings -as both HIV and tuberculosis were found to be the most common risk factors for DVT in another SA study. (9) In overseas settings, obesity and a history of DVT are the most common PE risk factors, with cardiac failure only present in a small proportion of patients. (12) Therefore, we once again demonstrate some differences in PE between SA and overseas settings. Again, this would also have important diagnostic implications in SA settings, with comorbid risk factors also contributing to overseas clinical prediction rules. (16) The PE population in overseas settings is comprised of patients with massive PE, submassive PE, and minor PE in the following proportions: 5.0%, 40.0% and 55.0%, respectively. (17) Most patients in our CS presented with submassive PE, with massive PE and minor PE occurring less frequently. This is in keeping with the overseas literature. (17) Almost two-thirds of our CS were classified as having submassive PE, with less than 1 in 10 patients classified as having massive PE according to currently accepted definitions, which are based on the presence/absence of haemodynamic instability and cardiac dysfunction/injury. (10) The presence of haemodynamic instability is often a proxy for the degree of occlusion caused by a PE in the pulmonary circulation. (10) Our CS suggests that most patients presenting with a PE in our setting do not have more severe manifestations of PE with associated haemodynamic instability. This is an important finding that requires confirmation in a prospective trial.
Inpatient mortality in our CS was high, even though treatment was administered. This agrees with findings from overseas studies, which also report high mortality in patients with PE. (18) (19) (20) (21) Another important finding of our CS, was that the majority of deaths were in patients who had submassive PE (i.e. haemodynamically stable patients). Our findings suggest that in addition to PE with haemodynamic instability (i.e. massive PE), which has traditionally been considered to account for most inpatient deaths in overseas settings, (17) PE in haemodynamically stable patients might be of concern in SA settings. Haemodynamically stable patients with PE in our setting are potentially
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salvageable, and our findings suggest that they should be considered for more aggressive management. As in overseas settings, (10) anticoagulation therapy formed the backbone of PE treatment in SA patients. Also in keeping with overseas management practices, intervention by thrombolysis or embolectomy was only performed when there was a relevant indication to perform either of these interventions. (10, 22) A limitation of our CS is that our modest sample size prevented us from performing further statistical investigations of characteristics associated with inpatient mortality. Another limitation of our CS is that it was from a single, tertiary-level healthcare facility. Therefore, our findings might not be applicable to SA patients with PE attending lower-level healthcare facilities. We chose to include only patients who were admitted with a primary diagnosis of PE (and not patients who were existing inpatients) in our CS. This might have introduced selection bias into the research. Due to the retrospective nature of this CS, there might have been under-reporting of some PE symptoms/signs. Another potential limitation of our CS is that the data capture of ICD primary diagnosis codes might have been incorrect, and there might have been some admissions for PE that were missed. Data were missing for some characteristics; however, we did not exclude patients with missing data from our analysis and accounted for missing data with the "not reported" category. Finally, we only report on inpatient outcomes and do not report patient outcomes following discharge from hospital. Large, multicentre, prospective studies are required to address the afore-mentioned limitations.
CONCLUSION
We provide a report of PE in SA patients. There were differences in PE presentation and risk factors between SA and overseas settings. Some clinical symptoms/signs and risk factors are included in clinical prediction rules for PE that were derived in overseas settings. If there are differences in PE clinical symptoms/signs and risk factors between SA and overseas populations, then overseas clinical prediction rules might be inappropriate for application in SA settings. Setting-specific clinical prediction rules for PE might be required. Inpatient mortality in SA patients with PE was high, even when treatment was administered. Most patients who died had submassive PE. As patients with submassive PE are haemodynamically stable, they are potentially salvageable. These patients should be considered for more aggressive management. Further research is required to confirm our findings, as well as to address the limitations of our research.
